Article
Oncology
Noriyuki Hirahara, Takeshi Matsubara, Shunsuke Kaji, Tetsu Yamamoto, Ryoji Hyakudomi, Kiyoe Takai, Kazunari Ishitobi, Yuki Uchida, Yoshitsugu Tajima
Summary: The study evaluated the feasibility, safety, and efficacy of postoperative adjuvant chemotherapy with docetaxel/cisplatin/S-1 (DCS) in patients with stage III gastric cancer after curative gastrectomy. Results showed that DCS regimen was acceptable with significant efficacy, indicating it as an effective postoperative treatment option for stage III gastric cancer patients.
Article
Gastroenterology & Hepatology
Keisuke Noda, Tetsuro Tominaga, Takashi Nonaka, Mitsutoshi Ishii, Hidetoshi Fukuoka, Makoto Hisanaga, Hiroaki Takeshita, Kazuo To, Kenji Tanaka, Terumitsu Sawai, Takeshi Nagayasu
Summary: This study compared long-term outcomes between curative and non-curative resection and evaluated the effects of adjuvant chemotherapy after curative resection. The results showed that the frequency of broad metastases was lower in the curative resection group, and the 5-year overall survival rate was higher. Among patients who underwent curative resection, the 5-year overall survival rate was significantly higher in the adjuvant chemotherapy group.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2023)
Article
Oncology
Yoon-Koo Kang, Jeong Hwan Yook, Young-Kyu Park, Jong Seok Lee, Young-Woo Kim, Jin Young Kim, Min-Hee Ryu, Sun Young Rha, Ik Joo Chung, In-Ho Kim, Sang Cheul Oh, Young Soo Park, Taeil Son, Mi Ran Jung, Mi Hwa Heo, Hark Kyun Kim, ChoHyun Park, Chang Hak Yoo, Jin-Hyuk Choi, Dae Young Zang, You Jin Jang, Ji Young Sul, Jong Gwang Kim, Beom Su Kim, Seung-Hoon Beom, Sang Hee Cho, Seung Wan Ryu, Myeong-Cherl Kook, Baek-Yeol Ryoo, Hyun Ki Kim, Moon-Won Yoo, Nam Su Lee, Sang Ho Lee, Gyunji Kim, YeonJu Lee, Jee Hyun Lee, Sung Hoon Noh
Summary: The PRODIGY study demonstrated that neoadjuvant DOS chemotherapy as part of perioperative chemotherapy is effective and well tolerated in Korean patients with LAGC.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Keiji Nishibeppu, Shuhei Komatsu, Toshiyuki Kosuga, Takeshi Kubota, Kazuma Okamoto, Hirotaka Konishi, Atsushi Shiozaki, Hitoshi Fujiwara, Eigo Otsuji
Summary: This study evaluated the prognostic effect of cumulative total S-1 dose (CTSD) on adjuvant chemotherapy after curative gastrectomy. The findings suggest that a CTSD of more than 20000 mg may contribute to better prognosis.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Multidisciplinary Sciences
Chihiro Sato, Hisato Kawakami, Ryo Tanaka, Hironaga Satake, Kentaro Inoue, Yutaka Kimura, Junya Fujita, Ryohei Kawabata, Yasutaka Chiba, Taroh Satoh, Kazuhiko Nakagawa
Summary: Adjuvant S-1 monotherapy is the standard treatment for stage II gastric cancer after curative resection in Japan. The efficacy of S-1 for microsatellite instability-high (MSI-H) tumors remained unknown. This study found that MSI-H stage II gastric cancer patients had better adjusted survival than microsatellite-stable (MSS) patients treated with S-1 adjuvant therapy. The mechanisms of recurrence differed between MSI-H and MSS tumors.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Xin Zhang, Hejing Huang, Dejun Yang, Peng Wang, Xin Huang, Zunqi Hu, Yu Zhang, Ronglin Yan, Zhenxin Zhu, Qingping Cai
Summary: For patients with gastric cancer and peritoneal metastasis, neoadjuvant intraperitoneal and systemic chemotherapy (NIPS) shows better survival rates and surgical resection rates compared to neoadjuvant systemic chemotherapy (NSC).
TECHNOLOGY IN CANCER RESEARCH & TREATMENT
(2021)
Article
Oncology
Noriyuki Hirahara, Takeshi Matsubara, Shunsuke Kaji, Hikota Hayashi, Koki Kawakami, Yohei Sasaki, Satoshi Takao, Natsuko Takao, Ryoji Hyakudomi, Tetsu Yamamoto, Yoshitsugu Tajima
Summary: This study aimed to evaluate the feasibility of adjuvant chemotherapy with S-1 in patients after esophagectomy. The results showed that S-1 could be safely and continuously administered as adjuvant chemotherapy for patients with esophageal cancer regardless of neoadjuvant chemotherapy (NAC).
Article
Oncology
Toshifumi Yamaguchi, Atsuo Takashima, Kengo Nagashima, Masanori Terashima, Masaki Aizawa, Manabu Ohashi, Ryo Tanaka, Tatsuya Yamada, Takahiro Kinoshita, Hisayuki Matsushita, Koshiro Ishiyama, Kei Hosoda, Yasuhiro Yuasa, Shusuke Haruta, Naoki Kakihara, Kazuhiro Nishikawa, Gen Yunome, Taroh Satoh, Takeo Fukagawa, Hitoshi Katai, Narikazu Boku
Summary: This study investigated the efficacy of preoperative chemotherapy as initial treatment in GC patients with CY1 and/or P1a. Results showed that preoperative chemotherapy did not provide a survival benefit for GC patients with CY1 and/or P1a, but showed favorable survival in patients who converted to P0 and CY0.
Article
Oncology
Yoshihiro Kakeji, Kazuhiro Yoshida, Yasuhiro Kodera, Mitsugu Kochi, Takeshi Sano, Wataru Ichikawa, Sang-Woong Lee, Kazushige Shibahara, Toshio Shikano, Masato Kataoka, Atsushi Ishiguro, Hitoshi Ojima, Yoshinori Sakai, Nobuyuki Musha, Tsunenobu Takase, Taisei Kimura, Masahiro Takeuchi, Masashi Fujii
Summary: The study demonstrated that adjuvant therapy with S-1 plus docetaxel significantly improves 3-year relapse-free survival and overall survival in patients with stage III gastric cancer.
Article
Oncology
Massimiliano Valletti, Dilmurodjon Eshmuminov, Nicola Gnecco, Christian Alexander Gutschow, Paul Magnus Schneider, Kuno Lehmann
Summary: This study analyzed the role of peritoneal disease in patients with gastric cancer and the prognostic relevance of response to neoadjuvant therapy. Results showed that conversion of CY+ to CY- after neoadjuvant chemotherapy with FLOT significantly improved overall survival, suggesting that surgical treatment should be considered in well-selected patients. However, peritoneal recurrence remains frequent despite the conversion.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Linda Feldbruegge, Felix Gronau, Andreas Brandl, Timo Alexander Auer, Alan Oeff, Peter Thuss-Patience, Johann Pratschke, Beate Rau
Summary: This retrospective single center cohort study on patients with peritoneal metastasis of gastric cancer who received PIPAC treatment suggests that addition of ramucirumab to pre-PIPAC systemic therapy, regardless of the treatment-free interval before PIPAC, does not increase the risk of postoperative complications.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Litong Shi, Zehua Wang, Lei Wang, Yongxu Jia, Jing Li, Yanru Qin
Summary: This study aimed to investigate the prognostic value of clinicopathological data, inflammation and nutritional indicators, and develop an effective prognostic nomogram and heat map for predicting cancer-specific survival (CSS) and disease-free survival (DFS) in stage II/III gastric cancer patients. The results demonstrated that the nomogram had high discriminative power and accuracy in predicting CSS and DFS, and the introduced heat map provided valuable insights for clinical decision-making.
CANCER MANAGEMENT AND RESEARCH
(2022)
Review
Oncology
Sang-Ho Jeong, Rock Bum Kim, Sung Eun Oh, Ji Yeong An, Kyung Won Seo, Jae-Seok Min
Summary: This study compared the efficacy of S-1 and CAPOX regimens in stage II or III gastric cancer patients. The results showed that there was no significant difference in five-year overall survival (OS) and disease-free survival (DFS) between the two regimens in all stages. This indicates that S-1 and CAPOX regimens have comparable efficacy in treating stage II or III gastric cancer patients.
Article
Gastroenterology & Hepatology
Han Kwang Yang, Jiafu Ji, Sang Uk Han, Masanori Terashima, Guoxin Li, Hyung Ho Kim, Simon Law, Asim Shabbir, Kyo Young Song, Woo Jin Hyung, Nik Ritza Kosai, Koji Kono, Kazunari Misawa, Hiroshi Yabusaki, Takahiro Kinoshita, Peng Choong Lau, Young Woo Kim, Jaideep Raj Rao, Enders Ng, Takanobu Yamada, Kazuhiro Yoshida, Do Joong Park, Bee Choo Tai, Jimmy Bok Yan So
Summary: This study aimed to evaluate the survival benefit of extensive intraoperative peritoneal lavage (EIPL) in patients with gastric cancer undergoing curative gastrectomy. After various analyses, it was concluded that EIPL and surgery did not have a survival benefit compared with surgery alone, and is not recommended for patients undergoing curative gastrectomy for gastric cancer.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2021)
Article
Oncology
Eeeln Buckarma, Cornelius A. Thiels, Zhaohui Jin, Travis E. Grotz
Summary: CRS and HIPEC with paclitaxel and cisplatin is well tolerated and associated with favorable oncologic and perioperative outcomes.
ANNALS OF SURGICAL ONCOLOGY
(2023)
